Alsakarneh S, Jaber F, Qasim H, Massad A, Alzghoul H, Abboud Y
J Clin Med. 2024; 13(9).
PMID: 38731022
PMC: 11084503.
DOI: 10.3390/jcm13092495.
De Novellis D, Folliero V, Giudice V, Pezzullo L, Sanna G, Fontana R
Clin Exp Med. 2023; 23(8):4943-4953.
PMID: 37898572
PMC: 10725343.
DOI: 10.1007/s10238-023-01223-w.
Alfonso-Dunn R, Lin J, Lei J, Liu J, Roche M, De Oliveira A
Front Immunol. 2023; 14:1194671.
PMID: 37449202
PMC: 10338057.
DOI: 10.3389/fimmu.2023.1194671.
Avigan Z, Paredes R, Boussi L, Lam B, Shea M, Weinstock M
Cancer Med. 2023; 12(16):16869-16875.
PMID: 37392171
PMC: 10501268.
DOI: 10.1002/cam4.6311.
Gonzalez-Bocco I, Beluch K, Cho A, Lahoud C, Reyes F, Moshovitis D
Pilot Feasibility Stud. 2023; 9(1):100.
PMID: 37328890
PMC: 10273764.
DOI: 10.1186/s40814-023-01325-y.
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.
Thookhamme C, Navinpipat M, Sasakul A, Pattarakosol P, Lertchaisataporn K, Tawinprai K
Clin Exp Vaccine Res. 2023; 12(2):107-115.
PMID: 37214149
PMC: 10193112.
DOI: 10.7774/cevr.2023.12.2.107.
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Liatsou E, Ntanasis-Stathopoulos I, Lykos S, Ntanasis-Stathopoulos A, Gavriatopoulou M, Psaltopoulou T
Cancers (Basel). 2023; 15(8).
PMID: 37190194
PMC: 10136728.
DOI: 10.3390/cancers15082266.
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H
Ann Hematol. 2023; 102(6):1421-1431.
PMID: 37041299
PMC: 10089694.
DOI: 10.1007/s00277-023-05204-7.
Immunogenicity profile after COVID-19 vaccination in patients with onco-hematological diseases.
Almeida Neto J, Arce I, Figueiredo V, Vicari P
Einstein (Sao Paulo). 2023; 21:eAO0089.
PMID: 36946824
PMC: 10010256.
DOI: 10.31744/einstein_journal/2023AO0089.
Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.
Kobayashi M, Mori A, Onozawa M, Tsukamoto S, Senjo H, Ishio T
Ann Hematol. 2023; 102(4):819-827.
PMID: 36862167
PMC: 9978274.
DOI: 10.1007/s00277-023-05142-4.
Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines.
Zeng Q, Yang X, Lin B, Li Y, Huang G, Xu Y
Vaccines (Basel). 2023; 11(2).
PMID: 36851338
PMC: 9963224.
DOI: 10.3390/vaccines11020461.
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.
Arvanitis P, Lerner A, Vieira K, Almaghlouth N, Farmakiotis D
Clin Exp Med. 2023; 23(6):2739-2748.
PMID: 36780118
PMC: 9923655.
DOI: 10.1007/s10238-023-01019-y.
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.
Arvanitis P, Lerner A, Vieira K, Almaghlouth N, Farmakiotis D
Res Sq. 2023; .
PMID: 36711556
PMC: 9882636.
DOI: 10.21203/rs.3.rs-2433445/v1.
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N, Pitakkitnukun P, Tangcheewinsirikul N, Chiasakul T, Rojnuckarin P
Blood Cancer J. 2022; 12(12):173.
PMID: 36550105
PMC: 9780106.
DOI: 10.1038/s41408-022-00776-5.
Neutralizing monoclonal antibodies for early treatment of hospital-acquired SARS-CoV-2 infection in hematologic patients.
Bussini L, Testi D, Tazza B, Oltolini C, Mastaglio S, Sepulcri C
EJHaem. 2022; .
PMID: 36248618
PMC: 9537893.
DOI: 10.1002/jha2.554.
Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature.
Whang S, Shah V, Pu L, Sheth P, Lucas G, Lee J
Pathogens. 2022; 11(9).
PMID: 36145390
PMC: 9503397.
DOI: 10.3390/pathogens11090958.
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates.
Lodde G, Fiedler M, Dittmer U, Placke J, Jansen P, Becker J
Front Oncol. 2022; 12:879876.
PMID: 36091146
PMC: 9448664.
DOI: 10.3389/fonc.2022.879876.
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
Alfonso-Dunn R, Lin J, Kirschner V, Lei J, Feuer G, Malin M
Front Immunol. 2022; 13:926318.
PMID: 35990701
PMC: 9388928.
DOI: 10.3389/fimmu.2022.926318.
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.
Thompson M, Hallmeyer S, Fitzpatrick V, Liao Y, Mullane M, Medlin S
J Patient Cent Res Rev. 2022; 9(3):149-157.
PMID: 35935520
PMC: 9302908.
DOI: 10.17294/2330-0698.1952.
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi S, Bashash D
Int Immunopharmacol. 2022; 110:109046.
PMID: 35843148
PMC: 9273573.
DOI: 10.1016/j.intimp.2022.109046.
